Aceruloplasminemia: New clinical, pathophysiological and therapeutic insights

Journal of Hepatology

Volumn 36, Issue 6, 2002, Pages 851-856

  Loréal, Olivier ^a   Turlin, Bruno ^a   Pigeon, Christelle ^a   Moisan, Annick ^b   Ropert, Martine ^a   Morice, Patrick ^c   Gandon, Yves ^a   Jouanolle, Anne Marie ^a   Vérin, Marc ^a   Hider, Robert C ^d   Yoshida, Kunihiro ^e   Brissot, Pierre ^a  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^b CENTRE EUGÈNE MARQUIS   (France)

^c CHR   (France)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e SHINSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Ceruloplasmin; Deferoxamine; Iron chelation; Iron overload; Liver

Indexed keywords

CERULOPLASMIN; DEFEROXAMINE; IRON; IRON 59;

ACERULOPLASMINEMIA; ADULT; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; CASE REPORT; DRUG EFFICACY; FEMALE; GENE MUTATION; GENOTYPE; HETEROZYGOTE; HUMAN; IRON BLOOD LEVEL; IRON METABOLISM; IRON OVERLOAD; PATHOPHYSIOLOGY; PLASMA CLEARANCE; PRIORITY JOURNAL;

CERULOPLASMIN; DEFEROXAMINE; FEMALE; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; LIVER; MAGNETIC RESONANCE IMAGING; MIDDLE AGED;

EID: 0036623360     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(02)00042-9     Document Type: Article

References (37)

1. Griffiths W, Cox T. Haemochromatosis: novel gene discovery and the molecular pathophysiology of iron metabolism. Hum Mol Genet 2000;9:2377-2382.
2. Harris ZL, Takahashi Y, Miyajima H, Serizawa M, MacGillivray RT, Gitlin JD. Aceruloplasminemia: molecular characterization of this disorder of iron metabolism. Proc Natl Acad Sci USA 1995;92:2539-2543.
3. Yoshida K, Furihata K, Takeda S, Nakamura A, Yamamoto K, Morita H, et al. A mutation in the ceruloplasmin gene is associated with systemic hemosiderosis in humans. Nat Genet 1995;9:267-272.
4. Miyajima H, Nishimura Y, Mizoguchi K, Sakamoto M, Shimizu T, Honda N. Familial apoceruloplasmin deficiency associated with blepharospasm and retinal degeneration. Neurology 1987;37:761- 767.
5. Logan JI, Harveyson KB, Wisdom GB, Hughes AE, Archbold GP. Hereditary caeruloplasmin deficiency, dementia and diabetes mellitus. Q J Med 1994;87:663-670.
6. Morita H, Ikeda S, Yamamoto K, Morita S, Yoshida K, Nomoto S, et al. Hereditary ceruloplasmin deficiency with hemosiderosis: a clinicopathological study of a Japanese family. Ann Neurol 1995;37:646-656.
7. Mukhopadhyay CK, Attieh ZK, Fox PL. Role of ceruloplasmin in cellular iron uptake. Science 1998;279:714-717.
8. Kaplan J, O'Halloran TV. Iron metabolism in eukaryotes: Mars and Venus at it again. Science 1996;271:1510-1512.
9. Harris ZL, Durley AP, Man TK, Gitlin JD. Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux. Proc Natl Acad Sci USA 1999;96:10812-10817.
10. Osaki S, Johnson DEF. The possible significance of the ferrous oxidase activity of ceruloplasmin in normal human serum. J Biol Chem 1996;241:2746-2751.
11. Gosriwatana I, Loréal O, Lu S, Brissot P, Porter J, Hider RC. Quantification of non-transferrin-bound iron in the presence of unsaturated transferrin. Anal Biochem 1999;273:212-220.
12. Erel O. Automated measurement of serum ferroxidase activity. Clin Chem 1998;44:2313-2319.
13. Cavill I. Plasma clearance studies. Lewis SM, Bayly RJ, editors. Radioisotopes in haematology. Churchill Livingstone and London: Saunders, 1977. vol. 14. pp. 214-244.
14. Stuart A, Bentley A, Miller D. Radionucleide blood cell survival studies. Lewis SM, Bayly RJ, editors. Radioisotopes in haematology. Churchill Livingstone and London: Saunders, 1977. pp. 245-262.
15. Gandon Y, Guyader D, Heautot JF, Reda MI, Yaouanq J, Buhe T, et al. Hemochromatosis: diagnosis and quantification of liver iron with gradient-echo MR imaging. Radiology 1994;193:533-538.
16. Koschinsky ML, Funk WD, van Oost BA, MacGillivray RT. Complete cDNA sequence of human preceruloplasmin. Proc Natl Acad Sci USA 1986;83:5086-5090.
17. Brissot P, Bourel M, Herry D, Verger JP, Messner M, Beaumont C, et al. Assessment of liver iron content in 271 patients: a reevaluation of direct and indirect methods. Gastroenterology 1981;80:557-565.
18. Brissot P, Deugnier Y, Le Treut A, Regnouard F, Simon M, Bourel M. Ascorbic acid status in idiopathic hemochromatosis. Digestion 1978;17:479-487.
19. Frieden E. Ceruloplasmin: a multifunctional metalloprotein of vertebrate plasma. Sigel H, editor. Metal ions in biological systems. New York, NY: Marcel Dekker, 1981. pp. 117-142.
20. Daimon M, Kato T, Kawanami T, Tominaga M, Igarashi M, Yamatani K, et al. A nonsense mutation of the ceruloplasmin gene in hereditary ceruloplasmin deficiency with diabetes mellitus. Biochem Biophys Res Commun 1995;217:89-95.
21. Miyajima H, Kohno S, Takahashi Y, Yonekawa O, Kanno T. Estimation of the gene frequency of aceruloplasminemia in Japan. Neurology 1999;53:617-619.
22. Klomp LW, Gitlin JD. Expression of the ceruloplasmin gene in the human retina and brain: implications for a pathogenic model in aceruloplasminemia. Hum Mol Genet 1996;5:1989-1996.
23. Patel BN, David S. A novel glycosylphosphatidylinositol-anchored form of ceruloplasmin is expressed by mammalian astrocytes. J Biol Chem 1997;272:20185-20190.
24. Patel BN, Dunn RJ, David S. Alternative RNA splicing generates a glycosylphosphatidylinositol-anchored form of ceruloplasmin in mammalian brain. J Biol Chem 2000;275:4305-4310.
25. Brissot P, Bolder U, Schteingart CD, Arnaud J, Hofmann AF. Intestinal absorption and enterohepatic cycling of biliary iron originating from plasma non-transferrin-bound iron in rats. Hepatology 1997;25:1457-1461.
26. Levy JE, Montross LK, Andrews NC. Genes that modify the hemochromatosis phenotype in mice. J Clin Invest 2000;105:1209-1216.
27. Miyajima H, Adachi J, Tatsuno Y, Takahashi Y, Fujimoto M, Kaneko E, et al. Increased very long-chain fatty acids in erythrocyte membranes of patients with aceruloplasminemia. Neurology 1998;50:130-136.
28. Miyajima H, Takahashi Y, Serizawa M, Kaneko E, Gitlin JD. Increased plasma lipid peroxidation in patients with aceruloplasminemia. Free Radic Biol Med 1996;20:757-760.
29. Deugnier YM, Loréal O, Turlin B, Guyader D, Jouanolle H, Moirand R, et al. Liver pathology in genetic hemochromatosis: a review of 135 homozygous cases and their bioclinical correlations. Gastroenterology 1992;102:2050-2059.
30. Deugnier YM, Charalambous P, Le Quilleuc D, Turlin B, Searle J, Brissot P, et al. Preneoplastic significance of hepatic iron-free foci in genetic hemochromatosis: a study of 185 patients. Hepatology 1993;18:1363-1369.
31. Moirand R, Mortaji AM, Loréal O, Paillard F, Brissot P, Deugnier Y. A new syndrome of liver iron overload with normal transferrin saturation. Lancet 1997;349:95-97.
32. Turlin B, Mendler MH, Moirand R, Guyader D, Guillygomarc'h A, Deugnier Y. Histologic features of the liver in insulin resistance-associated iron overload. A study of 139 patients. Am J Clin Pathol 2001;116:263-270.
33. Niederau C, Fischer R, Pürschel A, Stremmel W, Häussinger D, Strohmeyer G. Long term survival in patients with hereditary hemochromatosis. Gastroenterology 1996;110:1107-1119.
34. Daimon M, Kato T, Kawanami T, Tominaga M, Igarashi M, Yamanati K, et al. Biochem Biophys Res Commun 1995;217:89-95.
35. Kahn SE, Prigeon RL, Schwartz RS, Fujimoto WY, Knopp RH, Brunzell JD, et al. Obesity, body fat distribution, insulin sensitivity and islet b-cell function as explanations for metabolic diversity. J Nutr 2001;131:354S-360S.
36. Miyajima H, Takahashi Y, Kamata T, Shimizu H, Sakai N, Gitlin JD. Use of desferrioxamine in the treatment of aceruloplasminemia. Ann Neurol 1997;41:404-407.
37. Habgood MD, Liu ZD, Dehkordi LS, Khodr HH, Abbott J, Hider RC. Investigation into the correlation between the structure of hydroxypyridinones and blood-brain barrier permeability. Biochem Pharmacol 1999;57:1305-1310.